Genomatix Gives a Hand in the Analysis of Wayne State’s Sequencing Projects
News Mar 12, 2010
The C.S. Mott Center for Human Growth and Development, Department of Obstetrics and Gynecology, at the Wayne State University School of Medicine, in collaboration with the Center for Molecular Medicine and Genetics, the Karmanos Cancer Institute and the Institute for Environmental Health Sciences, installed a Genomatix Mining Station (GMS) and a Genomatix Genome Analyzer (GGA) last year at their labs in Detroit, MI in order to support the analysis of Next Generation Sequencing (NGS) data.
The GMS and GGA together represent the only complete, integrated analysis solution for NGS data analysis, starting with the raw data generated by the sequencer and leading to a molecular level understanding of the biology being studied.
Within the Department of Obstetrics and Gynecology, Professor Stephen Krawetz is the Director of Translational Reproductive Systems. His lab is utilizing the Genomatix systems to help analyze the cis and epigenetic elements that control many reproductive events, including cell-fate.
“After a year of routine use we have found the comprehensive, open, and integrated nature of the Genomatix systems to be very helpful in the analysis of our sequencing projects. One of our current projects is to provide a comprehensive description of both spermatozoal mRNAs and small non-coding RNAs. In collaboration with Susan Land, Director of the Applied Genomics Technology Core, we have generated a considerable amount of data using the Illumina NGS platforms,” said Dr. Krawetz, “Access to the integrated analysis core is helping us to get from data to the biology.”
Peter Grant, Chief Executive Officer at Genomatix, USA commented: "We are very happy that these systems have now proven their practical value after almost a year in this very successful lab at the Wayne State University. This is confirming that Genomatix' technology provides a stable analysis platform for this important new genomic technology.”
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.